Anti-APOC3 antibody
Specifications
| Product Cat#: | AB-06-0341 |
| Product type: | Primary antibody |
| Antigen: | APOC3 |
| Immunogen: | Recombinant protein with Human APOC3 aa 1-100 |
| Species immunized: | Rabbit |
| Isotype: | IgG |
| Applications: | Western Blot (1:400-1:2000); Immunohistochemistry (1:100-1:200); Flow Cytometry (1:40-1:100) |
| Reactivity: | Human |
| Clonality (clone number): | Polyclonal |
| Form: | Liquid |
| Buffer: | Tris-HCl buffer (pH7.4), 0.5% BSA, 50% glycerol, 0.05% NaN3. |
| Concentration: | 1 mg/ml |
| Purity: | Protein A/G affinity purified |
| Storage: | Aliquot and freeze at -20℃. Avoid multiple freeze/thaw cycles. |
| Alternative names: | APOC3 antibody |
| APO C3 antibody | |
| Apo CIII antibody | |
| Apo-CIII antibody | |
| APOC 3 antibody | |
| ApoC III antibody | |
| ApoC-III antibody | |
| APOC3 antibody | |
| APOC3_HUMAN antibody | |
| ApoCIII antibody | |
| Apolipoprotein C III antibody | |
| Apolipoprotein C-III antibody | |
| Apolipoprotein C3 antibody | |
| ApolipoproteinCIII antibody | |
| MGC150353 antibody |
Target information
Component of triglyceride-rich very low density lipoproteins (VLDL) and high density lipoproteins (HDL) in plasma (PubMed:18201179, PubMed:22510806). Plays a multifaceted role in triglyceride homeostasis (PubMed:18201179, PubMed:22510806). Intracellularly, promotes hepatic very low density lipoprotein 1 (VLDL1) assembly and secretion; extracellularly, attenuates hydrolysis and clearance of triglyceride-rich lipoproteins (TRLs) (PubMed:18201179, PubMed:22510806). Impairs the lipolysis of TRLs by inhibiting lipoprotein lipase and the hepatic uptake of TRLs by remnant receptors (PubMed:18201179, PubMed:22510806). Formed of several curved helices connected via semiflexible hinges, so that it can wrap tightly around the curved micelle surface and easily adapt to the different diameters of its natural binding partners (PubMed:18408013).
Provider
Erpantech Laboratory
